PW Medtech Group Limited (1358.HK) has a MoatMap StockRank of 73/100 based on Quality (61/100), Value (63/100), and Momentum (33/100) factor scores. The current signal is BUY. PW Medtech is a Chinese medical device company focusing on blood purification and infusion sets. It lacks the global scale, proprietary technology, and pricing power to benefit from the high-value CDMO pricing cycle.
PW Medtech Group Limited is a medical device company engaged in the research, development, manufacturing, and distribution of a range of medical instruments and supplies, particularly in the cardiovascular and orthopedic fields. The company focuses on innovative solutions and holds proprietary technologies for its key products, aiming to address unmet medical needs. Its R&D capabilities and specialized product portfolio position it as a significant player in the growing Chinese medical device market.
| Price | $0.15 |
| Market Cap | $214M |
| P/E (TTM) | 16.71 |
| Price/Book | 0.38 |
| Return on Equity | 2.8% |
| Return on Invested Capital | 3.3% |
| Debt/Equity | 0.45 |
| Gross Margin | 49.5% |
| Operating Margin | 10.3% |
| Revenue Growth | -5.0% |
| Dividend Yield | 5.5% |
| Free Cash Flow | $276K |
PW Medtech Group Limited operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (China).